Beta-blocker Before Extubation

Overview

Silent myocardial ischemia is known to occur in the general medical intensive care unit population immediately following tracheal extubation. We believe these patients are at risk for primary cardiac events in the 4 hours immediately following extubation. Metoprolol is a selective beta-1 antagonist, with little to no beta-2 activity at low and moderate doses. The cardioprotective effects of beta blockade have been well documented in randomized controlled trials. In patients undergoing extubation, prophylactic use of intravenous metoprolol may reduce post-extubation ischemia events as well as precursors of cardiogenic pulmonary edema (atrial and ventricular wall tension). Our primary hypothesis is that prophylactic metoprolol (titrated to reduce resting heart rate by at least 10%) prior to tracheal extubation will reduce the rate of ischemia as judged by ST segment analysis.

Full Title of Study: “Use of Prophylactic Beta Blockade to Prevent Peri-extubation Cardiac Ischemia and Congestive Heart Failure”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2009

Interventions

  • Drug: Metoprolol
    • Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.

Arms, Groups and Cohorts

  • No Intervention: Control
  • Active Comparator: Metoprolol

Clinical Trial Outcome Measures

Primary Measures

  • The rate of ischemia as judged by ST segment analysis in the 4h following extubation
    • Time Frame: 4 hours

Secondary Measures

  • Rate-pressure product following extubation
    • Time Frame: 30min, 2h, 4h
  • Troponin T elevations, the incidence of cardiogenic edema, and the rate of reintubation
    • Time Frame: 48h
  • Pro-BNP levels
    • Time Frame: 30min

Participating in This Clinical Trial

Inclusion Criteria

  • Adult medical or cardiac intensive care unit patients on mechanical ventilation who have known coronary artery disease or have at least 2 of the following risk factors for coronary artery disease: – Cigarette smoking – Hypertension (BP 140/90 or antihypertensive medication) – Low HDL-cholesterol (HDL-C) (<40 mg/dL [1.03 mmol/L]) – Family history of premature CHD (in male first degree relatives <55 years, in female first degree relative <65 years) – Age (men 45 years, women 55 years) – Diabetes mellitus – Symptomatic carotid artery disease – Peripheral arterial disease – Abdominal aortic aneurysm Exclusion Criteria:

  • Arterial hypotension, defined as mean arterial pressure < 60 mmHg or requiring any intravenous vasoactive medication. – The presence of known reactive airway disease. – Resting heart rate of <60 in the period prior to tracheal extubation.. – The presence of decompensated congestive heart failure, defined as requiring continuous infusion of an inotropic agent. – Known hypersensitivity to beta-blockers or any other contraindication to their use. – Subjects younger than 18 years of age. – Inability to obtain consent from the subject or the subjects authorized representative. – Pregnancy – Digoxin therapy – Current therapy with a beta-blocker

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gregory A. Schmidt
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Gregory A. Schmidt, Professor – University of Iowa
  • Overall Official(s)
    • Gregory A Schmidt, MD, Principal Investigator, University of Iowa

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.